Drugmaker Jubilant Lifesciences Ltd. and diagnostics chain Thyrocare Technologies Ltd. have emerged as analysts' favourites even as pharmaceutical companies continue to face pricing pressures and regulatory scrutiny in the U.S.
All analysts tracked by Bloomberg have a ‘Buy' rating on the two stocks. Based on the 12-month consensus target prices, Jubilant Lifesciences offers a return potential of 27 percent while Thyrocare can rise up to 21 percent.
Strides Shasun follows with 91 percent of the analysts recommending a ‘buy', while the rest advise to ‘hold'.
Unichem Laboratories Ltd., Sanofi India Ltd. and Fortis Healthcare Ltd. complete the list of top six with an expected upside of 13-27 percent.
None of these stocks have a ‘Sell' recommendation.
Comprehensive Budget 2026 coverage, LIVE TV analysis, Stock Market and Industry reactions, Income Tax changes and Latest News on NDTV Profit.
